Efficacy and Safety of Clomiphene Citrate for Late‐Onset Hypogonadism as Evaluated by Aging Male Symptom Rating Scale Over One Year
International Journal of Urology · 2026
DOI: 10.1111/iju.70289 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yuta Anno und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Juntendo University Urayasu Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Clomiphene, Hypogonadism, Testosterone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of clomiphene citrate for late‐onset hypogonadism by assessing changes in serum testosterone levels and Aging Males Symptoms scores over 1 year. Materials and Methods This retrospective study comprised 54 men (44.2 ± 0.9 years old) with hypogonadal symptoms. Clomiphene citrate was given as 50 mg tablets every other day for a maximum of 1 year. Blood test results and scores of the Aging Males Symptoms rating scale were basically obtained every 3 months. Factors defining elevated testosterone levels were analyzed among pretreatment endocrinological data and age. Adverse events were directly confirmed by the physicians.
Results
Serum testosterone levels increased and remained high over 1 year. Similarly, the score of the Aging Males Symptoms rating scale appeared to decline over 1 year. However, the score regarding sexual dysfunction did not show significant improvement. Multiple regression analysis showed that luteinizing hormone was the only independent factor influencing testosterone elevation. No adverse events occurred in our patients.
Conclusions
This is the first study, to our knowledge, showing the efficacy of treatment with clomiphene citrate for late‐onset hypogonadism based on the Aging Males Symptoms rating scale score. Because acceptable efficacy and no adverse events were found for 1 year, we emphasize that clomiphene citrate should be one alternative treatment for testosterone replacement in young patients desiring children or patients who are overly concerned about testicular atrophy, especially those with a low serum luteinizing hormone level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.
- Department of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
- D Clinic Tokyo, Tokyo, Japan.
ORCID-Profile: Yuta Anno, Akira Tsujimura, Keisuke Ishikawa, Masato Shirai
Zitieren
APA
Anno, Y., Tsujimura, A., Kasai, R., Ota, Y., Kanda, T., Wakita, H., Ishikawa, K., Taniguchi, A., Uesaka, Y., Nozaki, T., Shirai, M., Kobayashi, K., & Horie, S. (2026). Efficacy and Safety of Clomiphene Citrate for Late‐Onset Hypogonadism as Evaluated by Aging Male Symptom Rating Scale Over One Year. International Journal of Urology. https://doi.org/10.1111/iju.70289
Vancouver
Anno Y, Tsujimura A, Kasai R, Ota Y, Kanda T, Wakita H, et al. Efficacy and Safety of Clomiphene Citrate for Late‐Onset Hypogonadism as Evaluated by Aging Male Symptom Rating Scale Over One Year. International Journal of Urology. 2026. doi:10.1111/iju.70289
BibTeX
@article{Anno2026,
author = {Anno, Yuta and Tsujimura, Akira and Kasai, Riho and Ota, Yukiko and Kanda, Takashi and Wakita, Haruhiko and Ishikawa, Keisuke and Taniguchi, Ayumu and Uesaka, Yuka and Nozaki, Taiji and Shirai, Masato and Kobayashi, Kazuhiro and Horie, Shigeo},
title = {Efficacy and Safety of Clomiphene Citrate for Late‐Onset Hypogonadism as Evaluated by Aging Male Symptom Rating Scale Over One Year},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70289}
}
EUVIMED